Clinical attitude regarding denosumab drug-holiday for dental extraction in oncologic patients: a national survey

Introduction: Denosumab is indicated in oncology to reduce tumoral development. However, this medication may cause osteonecrosis of the jaw, especially after dental extractions. Drug holiday has been proposed decrease risk jaw. This survey aimed assess management drug holidays for patients who needed both extraction and denosumab. Methods: A questionnaire was sent a panel healthcare professionals. Results: Of 33 practitioners interviewed, 28 undertook or “were used to” extractions on 25% (7/28) questioned did not stop from taking denosumab before 75% (21/28) holiday. For those stopped treatment, 33% (7/21) waited 2 months performing 38% (8/21) reintroducing molecule; being median duration cases. In addition, 89% (25/28) practitioners, modified their surgical procedure these patients. Conclusion: Despite small number responders, it seemed that at least mandatory tooth extraction. The issue should always be raised with patient's oncologist.